The Clorox Company (NYSE:CLX) Stock Holdings Increased by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. increased its holdings in The Clorox Company (NYSE:CLX - Free Report) by 106.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,766 shares of the company's stock after buying an additional 44,246 shares during the quarter. Cambridge Investment Research Advisors Inc. owned about 0.07% of Clorox worth $12,629,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Redwood Park Advisors LLC acquired a new stake in shares of Clorox during the 4th quarter valued at $26,000. Millstone Evans Group LLC acquired a new stake in shares of Clorox in the fourth quarter valued at about $31,000. Wood Tarver Financial Group LLC acquired a new stake in Clorox during the fourth quarter worth about $31,000. GKV Capital Management Co. Inc. acquired a new stake in Clorox during the fourth quarter worth about $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Clorox during the fourth quarter valued at approximately $33,000. 78.53% of the stock is owned by institutional investors.

Clorox Trading Down 0.2%

Shares of Clorox stock opened at $122.08 on Wednesday. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44. The Clorox Company has a 1-year low of $120.33 and a 1-year high of $171.37. The company's fifty day simple moving average is $132.40 and its 200-day simple moving average is $146.13. The stock has a market capitalization of $15.05 billion, a PE ratio of 21.92, a P/E/G ratio of 2.77 and a beta of 0.54.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The firm had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. Clorox's revenue for the quarter was down 8.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.71 earnings per share. As a group, equities analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of Clorox stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company's stock, valued at approximately $546,280. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on CLX shares. UBS Group dropped their price objective on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Evercore ISI set a $140.00 target price on shares of Clorox and gave the stock an "underperform" rating in a research note on Tuesday, May 6th. Wells Fargo & Company reduced their price objective on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Finally, Citigroup lowered their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a report on Monday, April 14th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $153.00.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.